Immediate Guideline‑Directed Management of HFmrEF (EF 40‑45%)
Patient Classification
- HFmrEF is defined by the 2022 ACC/AHA/HFSA guideline as EF 41‑49%; patients with borderline EF 40‑45% should be managed as HFmrEF. [1][2]
Immediate Initiation of Guideline‑Directed Medical Therapy
First‑Line Pharmacologic Agents
- Start an angiotensin‑receptor‑neprilysin inhibitor (sacubitril/valsartan) or, if contraindicated, an ACE‑inhibitor or ARB as the foundational drug for HFmrEF. 1
- Begin a beta‑blocker (carvedilol, metoprolol succinate, or bisoprolol) at a low dose with gradual uptitration. 1
- Add a mineralocorticoid‑receptor antagonist (e.g., spironolactone 25 mg daily) when symptoms persist, with regular monitoring of serum potassium and renal function. 1
- Include an SGLT2 inhibitor (dapagliflozin or empagliflozin) as part of the core regimen, independent of diabetic status. 1
Symptom‑Driven Diuretic Therapy
- Use loop diuretic furosemide for volume overload; titrate dose according to clinical signs of congestion. [1][4]
Management of Modifiable Risk Factors
- Target blood‑pressure < 130/80 mmHg in all HF patients to prevent worsening diastolic function. 4
- Optimize heart‑rate control; beta‑blockers are especially beneficial in diastolic dysfunction. 4
- Identify and treat myocardial ischemia, as it aggravates ventricular relaxation. 4
Baseline Diagnostic Evaluations Prior to Cardiology Referral
- Measure natriuretic peptides (BNP or NT‑proBNP) to confirm HF diagnosis and establish a baseline. [3][1]
- Perform a 12‑lead ECG; a normal tracing makes systolic dysfunction unlikely. 3
- Obtain comprehensive labs (CBC, electrolytes, creatinine, glucose, liver enzymes, thyroid function). 3
- Obtain a chest radiograph to assess for cardiomegaly and pulmonary congestion. 3
Echocardiographic Indicators of Diastolic Dysfunction
- Recognize a pattern of reduced transmitral E‑wave velocity, increased A‑wave velocity, and a lowered E/A ratio, indicating mild diastolic dysfunction. 3
Prognostic Implications of Early Therapy
- Initiating guideline‑directed therapy promptly improves prognosis in HFmrEF. 1
Clinical Characteristics of HFmrEF
- Patients classified as HFmrEF display mild systolic impairment combined with diastolic dysfunction. 2
Referral Recommendations
- Refer for cardiac magnetic resonance imaging to evaluate suspected left‑ventricular non‑compaction. 3
- Refer for cardiac resynchronization therapy evaluation if QRS duration exceeds 120 ms. [3][6]
- Schedule cardiology follow‑up within 2–4 weeks, but do not delay the start of medical therapy. [1][2]